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Abstract
We tested the association between APOE-ε4 and processing speed and memory between ages 43 and 69 in a
population-based birth cohort. Analyses of processing speed (using a timed letter search task) and episodic memory (a
15-item word learning test) were conducted at ages 43, 53, 60–64 and 69 years using linear and multivariable
regression, adjusting for gender and childhood cognition. Linear mixed models, with random intercepts and slopes,
were conducted to test the association between APOE and the rate of decline in these cognitive scores from age 43 to
69. Model ﬁt was assessed with the Bayesian Information Criterion. A cross-sectional association between APOE-ε4 and
memory scores was detected at age 69 for both heterozygotes and homozygotes (β = −0.68 and β = −1.38,
respectively, p = 0.03) with stronger associations in homozygotes; no associations were observed before this age.
Homozygous carriers of APOE-ε4 had a faster rate of decline in memory between ages 43 and 69, when compared to
non-carriers, after adjusting for gender and childhood cognition (β = −0.05, p = 0.04). There were no cross-sectional or
longitudinal associations between APOE-ε4 and processing speed. We conclude that APOE-ε4 is associated with a
subtly faster rate of memory decline from midlife to early old age; this may be due to effects of APOE-ε4 becoming
manifest around the latter stage of life. Continuing follow-up will determine what proportion of this increase will
become clinically signiﬁcant.
Introduction
Apolipoprotein E (APOE) is involved in the transport of
cholesterol and other lipids between cellular structures.1
It is genetically associated with two single-nucleotide
polymorphisms (SNPs) that mark three alleles, ε2, ε3 and
ε4. The ε4 in particular has a higher rate of lipoprotein
clearance, thus altering both plasma cholesterol level and
disrupting brain re-innervation processes that rely on
lipids.2 APOE is also involved in clearing beta amyloid
from the brain, and the ε4 allele may be less efﬁcient at
this3. The combined effect of changes in these mechan-
isms means individuals heterozygous for the ε4 genotype
of APOE have three times the risk of developing sporadic
Alzheimer’s Disease (AD), increasing to 14 times the risk
for homozygotes2,4.
Associations between APOE-ε4 and incident AD
have been demonstrated in numerous epidemiological
studies 2,4–6, yet the effects of APOE-ε4 on decline across
the full spectrum of cognitive capability in the general
population are less clear. A multicohort consortium that
included the Medical Research Council National Survey
for Health and Development (NSHD) found that APOE
genotype had no signiﬁcant effects on multiple cognitive
and functional domains across midlife and old age 7,
consistent with other studies examining cognitive trajec-
tories in younger individuals 8–10. However, a compre-
hensive meta-analysis of the effects of APOE on cognition
across a wider range of age groups in population-based
cohorts suggested that the ε4 allele has a small but sig-
niﬁcant negative effect on cognition, more pronounced in
older age groups 11. While APOE-associated cognitive has
been noted within birth cohort studies in the ninth decade
12, a longitudinal analysis conducted on a mixed age group
sample of known APOE status additionally noted an
increased rate of decline in memory in homozygous ε4
carriers, manifesting prior to age 60 13. Yet with a follow
up of 5 years, and age heterogeneity among the sample
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population, further work to support or refute the ﬁndings
of this study would be valuable.
Since its inclusion in the above meta-analysis 7, the
NSHD has undergone two further waves of assessment,
providing a total of four repeated measures of verbal
episodic memory and processing speed spanning ages 43
and 69 years. This birth cohort offers two strong advan-
tages for investigating the associations between APOE
genotype and later-life cognition: age homogeneity and
individual cognitive trajectories available from midlife
(when age-associated cognitive impairment is minimal) to
early old age (when this is more pronounced but frank
dementia is still rare). This paper aims to determine the
association between APOE-ε4 and processing speed and
episodic memory scores from age 43 to 69 in this
population-based birth cohort, accounting for childhood
cognitive ability.
Methods
The MRC National Survey of Health and Development
(NSHD) is a birth cohort stratiﬁed by paternal social class,
focusing on multiple sociodemographic and health-
related processes across the life course. The initial study
consisted of 5362 individuals born in England, Scotland
and Wales in a single week of March 1946 14,15. Response
rates have remained consistently high during the study’s
duration, and the sample has remained representative of
this generation 16.
The sample for the current analysis is drawn from age
43, when 3749 participants remained in NSHD. From this
group, 3456 (92%) had at least one assessment of cogni-
tion at either 43, 53, 60–64 or 69. APOE genotype was
available for 2637 of the original study members. A fur-
ther 67 with the ε2/ε4 genotype were excluded, as asso-
ciations are difﬁcult to interpret due to opposing effects of
these alleles 17. Of the individuals with valid APOE data,
2557 (97%) had at least one valid cognitive measure
between ages 43 and 69, and 2365 (90%) had data for all
covariables. None of these individuals had a conﬁrmed
diagnosis of dementia.
With regard to longitudinal modelling, at least one
measure of episodic memory was available for 2352
individuals, with 100 having data from only one time
point, 441 from two time points, 498 from three time
points and 1313 from all four time points. For the 2363
individuals with a measure of processing speed 72 had
data from a single time point, 437 from two, 495 from
three and 1359 from all four time points.
Outcome: adult episodic memory and processing/search
speed
Cognitive function was tested at ages 43, 53, 60–64 and
69. Memory was assessed by a three-trial 15-item word
learning test (WLT, max. 45), with word lists alternated
over waves to minimise practice effects. Processing speed
was assessed by a timed letter search task (TLST), in
which study members were required to cross out ran-
domly distributed letters ‘P’ and ‘W’ in a grid of other
letters as quickly and accurately as possible in 1 min, with
a maximum score of 600.
APOE genotype
Blood samples were collected at age 53 by a trained
research nurse, and DNA was extracted 18. Genotyping of
the two SNPs, rs439358 and rs7412, used to determine
APOE genotype was conducted at LGC, Huddleston, UK.
For analysis, APOE genotype was re-coded for the
homozygous or heterozygous presence of ε4 alleles; ε4
carrier was deﬁned as ε3/ε4 or ε4/ε4, with ε2/ε4 excluded.
Carriers of ε2 were grouped alongside ‘non-APOE-ε4
carriers’, as independent analysis of these ε2 carriers
yielded no signiﬁcant results (likely due to the relative low
number of ε2 homozygotes within the sample). Thus,
APOE was categorised as ‘No APOE-ε4’, ‘Homozygous
APOE-ε4’ and ‘Heterozygous APOE-ε4’.
Covariables
Covariables were factors known to be associated with
cognitive performance in later life: gender, childhood
cognitive ability, formal educational qualiﬁcations19 and
the presence of vascular risk factors that might potentially
have a role in the association between APOE and cogni-
tion 20.
Childhood cognitive ability at age 8 was represented as
the standardised sum of four tests of verbal and non-
verbal ability devised by the National Foundation
for Educational Research that included reading compre-
hension, pronunciation, vocabulary and non-verbal rea-
soning 21. Data were used from age 8 unless missing,
where it was substituted for z-scores from the assessments
at age 11 (n= 128). Data still missing were substituted for
that collected at age 15 (n= 71). Test–retest correlation
coefﬁcients indicated high reliability for each of these
standardised scores 21,22,].
Highest educational qualiﬁcations by age 26 were clas-
siﬁed using the Burnham Scale 23 and were grouped into
three levels for analysis: ‘None’, ‘Vocational or O-Level/
GCSE or equivalents’, ‘A-Level or Higher Education or
equivalents’. Social class was recorded at age 53, or earlier
if this was missing, based on the Registrar General’s
classiﬁcation of own occupation. Vascular risk factors
were represented by clinical disorders at age 60–64,
summarised categorically as the presence of moderate to
severe diabetes, hypertension, obesity, hypercholester-
olaemia or cerebrovascular and cardiovascular disease 24.
Measures of total cholesterol were available at ages 53,
60–64 and 69 recorded in millimoles per litre to the
nearest decimal place.
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Ethics
For the most recent data collection, ethical approval was
obtained from the NRES Queen Square REC (14/LO/
1073) and Scotland A REC (14/SS/1009). At each stage of
data collection, written informed consent was provided by
all participating study members. Ethical approval of
NSHD data collection up to 2010 was obtained from the
Scotland A Research Ethics Committee, the Multicentre
Research Ethics Committee, and consent for the use of
genetic data in studies of health was obtained from the
Central Manchester Research Ethics Committee.
Statistical methods
Differences in social class, educational qualiﬁcations
and childhood cognitive ability by APOE genotype were
assessed using Χ2-test and t-tests. Associations between
APOE and each cognitive test score were analysed using
linear and multivariate regression models separately for
each of the four time points. Adjustments were initially
made sequentially for gender, childhood cognition, edu-
cation and vascular risk factors.
Linear mixed models were used to investigate the tra-
jectories of verbal memory and search speed scores and
their association with APOE. Intercepts and slopes were
random to account for inter-individual variability at
Table 1 Sample characteristics (by apoe-ε4 status)
No APOE-ε4 Heterozygous APOE-ε4 Homozygous APOE-ε4 Missing
Sample size 1699 (71.8%) 590 (25.0%) 76 (3.2%) 2997 (55.9%)
Female 953 (51.6%) 293 (45.9%) 45 (53.6%) 522 (47.9%)
p=0.04 p<0.01
Childhood cognition* µ (S.D.) 0 (1.0) 0 (1.0) 0.1 (1.0) 0 (1.0)
Education Status age 26:
None 636 (36.5%) 211 (34.8%) 31 (37.8%) 932 (43.7%)
Vocational/O-Level 491 (28.2%) 170 (28.0%) 23 (28.1%) 567 (26.6%)
A-Level/Higher 617 (35.4%) 226 (37.2%) 28 (34.2%) 635 (29.8%)
p=0.92 p<0.01
Social Class age 53
Unskilled 82 (4.5%) 24 (3.8%) 1 (1.2%) 76 (4.1%)
Partly skilled 209 (11.4%) 80 (12.5%) 11 (13.1%) 260 (14.1%)
Skilled manual 321 (17.6%) 110 (17.2%) 15 (17.9%) 401 (21.8%)
Skilled non-manual 424 (23.2%) 141 (22.1%) 16 (19.1%) 445 (24.1%)
Intermediate 674 (36.9%) 226 (35.4%) 35 (41.7%) 542 (29.4%)
Professional 118 (6.5%) 57 (8.9%) 6 (7.1%) 120 (6.5%)
p=0.55 p<0.01
Clinical disorders 60–64
Hypercholesterolaemia 230 (23.1%) 111 (31.3%) 12 (27.3%) 77 (23.7%)
p=0.01 p=0.48
Hypertension 701 (52.9%) 238 (52.1%) 28 (47.5%) 260 (52.7%)
p=0.70 p=0.94
Cardio/cerebrovascular 108 (8.6%) 42 (12.2%) 7 (13.5%) 45 (8.4%)
p=0.06 p=0.30
Diabetes 254 (23.9%) 95 (25.2%) 10 (21.3%) 87 (24.4%)
p=0.79 p=0.97
Obesity 396 (29.7%) 128 (28.0%) 17 (28.3%) 141 (28.5%)
p=0.76 p=0.64
*Derived from Childhood Cognitive Testing Battery, Standardised Value using mean = 1, S.D. = 0
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baseline and the rate of change. Linear and quadratic
models were examined and an unstructured covariance
structure was assumed. Associations with intercept and
slope were sequentially estimated for gender and child-
hood cognitive ability, education and vascular risk factors.
Model ﬁt was compared by using the Bayesian Informa-
tion Criterion (BIC). First, unconditional linear and
quadratic models were compared and then conditional
models were estimated. These were as follows: Model 1:
APOE.Model 2: adjusted for gender.Model 3: additionally
adjusted for childhood cognitive ability. Model 4: addi-
tionally adjusted for education. Model 5: additionally
adjusted for vascular risk factors. Analysis was initially
conducted on cases with data available for all covariates.
Where the inclusion of covariates were found to have no
effect on associations between APOE and cognition, the
covariate was removed from the ﬁnal model and those
persons omitted only due to missing data from this now
removed covariate were reincorporated. Statistical soft-
ware package Stata version 14.1 was used for all analyses.
Results
The APOE genotype frequencies within NSHD were as
follows: ε2/ε2 n= 20 (0.76%), ε2/ε3 n= 307 (11.64%), ε3/
ε3 n= 1520 (57.64%), ε2/ε4 n= 67 (2.54%), ε3/ε4 n= 639
(24.23%), ε4/ε4 n= 84 (3.19%). Sample characteristics for
all individuals with recorded APOE status are outlined in
Table 1.
Childhood cognitive ability, despite having no associa-
tion with APOE genotype, was still included in all models,
since this allows each individual to begin from an equal
cognitive level in the early life course, thus allowing more
precise assessment of the longitudinal effects of APOE
genotype on cognition. Of those with known APOE sta-
tus, 2365 (92%) had a valid measure of childhood cogni-
tive ability. Education bore no association with APOE
genotype and had no impact on associations between
APOE genotype and cognition in either cross sectional or
longitudinal models, and was consequently dropped from
ﬁnal models. Sensitivity analyses were conducted on
measured vascular risk factors, and the inclusion of all
Table 2 Cross-sectional results of apoe status on total word learning test score
Model one (APOE only) Model two (APOE + gender) Model three (APOE + gender +
childhood cognition)
β LCI UCI p β LCI UCI p β LCI UCI p
Age 43 (n=2123)
No APOE-ε4 Reference 0.61 Reference 0.53 Reference 0.98
Heterozygous APOE-ε4 0.07 −0.56 0.69 0.15 −0.47 0.77 0.00 −0.55 0.55
Homozygous APOE-ε4 0.77 −0.76 2.30 0.82 −0.70 2.34 0.14 −1.22 1.49
BIC 13,860.78 13833.91 13,351.80
Age 53 (n=2313)
No APOE-ε4 Reference 0.99 Reference 0.89 Reference 0.84
Heterozygous APOE-ε4 0.05 −0.55 0.64 0.15 −0.44 0.74 0.01 −0.50 0.53
Homozygous APOE-ε4 0.05 −1.40 1.51 0.08 −1.36 1.51 −0.38 −1.64 0.88
BIC 15,079.15 15,039.00 14,443.10
Age 60–64 (n=1672)
No APOE-ε4 Reference 0.74 Reference 0.45 Reference 0.47
Heterozygous APOE-ε4 0.27 −0.41 0.95 0.42 −0.24 1.10 0.33 −0.27 0.92
Homozygous APOE-ε4 0.16 −1.52 1.84 0.21 −1.45 1.87 −0.37 −1.85 1.11
BIC 10,785.73 10,746.18 10,367.02
Age 69 (n=1616)
No APOE-ε4 Reference 0.14 Reference 0.21 Reference 0.03
Heterozygous APOE-ε4 −0.64 −1.32 0.05 −0.56 −1.24 0.13 −0.68 −1.29 0.03
Homozygous APOE-ε4 −0.84 −2.53 0.86 −0.79 −2.47 0.89 −1.38 −2.89 0.07
BIC 10,443.28 10,415.69 10,077.33
All ﬁgures rounded to 2 decimal places
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vascular risk factors did not alter any associations seen
between APOE and cognition. Only the presence of
hypercholesterolaemia displayed variation between APOE
genotypes. Therefore, an additional sensitivity analysis of
cholesterol levels alone, available for ages 53, 60–64 and
69, was conducted on cross-sectional models at these
ages, but these too had no impact upon the association of
APOE genotype with cognition. In addition, the absence
of a cholesterol measurement at age 43 prevented its
inclusion in the longitudinal model of cognition, and thus
it was omitted from the ﬁnal models. As such, the ﬁnal
sample consisted of individuals with data on APOE gen-
otype and childhood and adult cognitive scores. Sensi-
tivity analyses showed no differences in the results when
missing childhood cognitive scores at age 8 were sub-
stituted for cognitive scores at age 11 and 15.
APOE and episodic memory and processing/search speed
at age 43, 53, 60–64 and 69
APOE-ε4 was inversely associated with WLT at age 69
only (Table 2). This persisted after adjusting for gender
and childhood cognitive ability in both heterozygotes and
homozygotes (β=−0.68 and β=−1.38, respectively, p=
0.03), with a stronger association seen in homozygotes. At
ages 43, 53 and 60–64 there were no associations between
APOE-ε4 and the memory scores, and no associations
between APOE and search speed scores at any age
(Supplementary Table S1).
APOE and cognitive decline
BIC statistics showed that a quadratic model better
described the trajectories of WLT and TLST from age 43
to 69 than a linear model. For TLST, APOE was not
associated with intercept or slope (Supplemental
Table S2).
For WLT, APOE was not signiﬁcantly associated with
intercept, but those homozygous for APOE4 showed a
faster linear rate of decline in WLT (β=−0.05, p= 0.04)
when compared with individuals with no APOE.
Although a similar trend was found for heterozygotes, the
rate of change in this group was not signiﬁcantly faster
when compared to non-carriers (β=−0.01, p= 0.22).
Although gender and childhood cognitive ability were
positively associated with WLT at intercept level, no
associations were found between these and slope.
Evidence of longitudinal WLT trajectories with regards
APOE genotype is provided in Table 3. Figure 1 depicts
the cognitive trajectories of WLT mean scores by APOE
genotype, with the intercept adjusted for gender and
childhood cognitive ability. This indicates a faster rate of
cognitive decline for those individuals homozygous for
APOE-ε4.
Discussion
We found that APOE-ε4 had a negative association with
verbal episodic memory, as measured by a word-learning
test, at age 69. No cross-sectional association was found at
Table 3 Longitudinal results of apoe status on total word learning test score between ages 43 and 69
Model one (APOE only) Model two (APOE + gender) Model three (APOE + gender +
childhood cognition)
Intercept terms β LCI UCI p β LCI UCI p β LCI UCI p
APOE-ε4 status
No APOE-ε4 Reference Reference Reference
Heterozygous APOE-ε4 0.74 −0.54 2.02 0.26 0.84 −0.44 2.11 0.20 0.69 −0.56 1.93 0.28
Homozygous APOE-ε4 2.72 −0.37 5.81 0.08 2.76 −0.32 5.85 0.08 2.34 −0.66 5.33 0.13
Gender (female) 1.82 1.37 2.27 <0.01 1.76 1.38 2.14 <0.01
Childhood cognition (8) 3.51 3.28 3.74 <0.01
Slope terms
Decline per year (linear) 0.34 0.25 0.47 <0.01 0.34 0.21 0.47 <0.01 0.35 0.22 0.47 <0.01
Decline per year (quadratic) 0.00 0.00 0.00 <0.01 0.00 0.00 −0.00 <0.01 0.00 0.00 0.00 <0.01
APOE−ε4 status
No APOEε4 slope Reference −0.03 Reference Reference
Heterozygous APOE-ε4 Slope −0.01 −0.11 0.01 0.23 −0.01 −0.03 0.01 0.23 −0.01 −0.03 0.01 0.22
Homozygous APOE-ε4 Slope −0.05 0.00 0.04 −0.05 −0.11 0.00 0.04 −0.05 −0.11 0.00 0.04
BIC 45,268.92 45,214.72 44,467.03
All ﬁgures rounded to two decimal places
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any age prior to this, and no association was noted for
processing speed as measured by a TLST. Longitudinally,
there was evidence of faster decline in episodic memory
between ages 43 and 69 in individuals homozygous for
APOE-ε4. Taken together, our ﬁndings suggest that
APOE-ε4 has a dose-dependent cumulatively detrimental
effect on episodic memory, which becomes evident as a
cross-sectional association by age 69.
The major strength of NSHD arises through it being a
population-based birth cohort with prospective measures
of cognition across life. To our knowledge, this is the ﬁrst
study to investigate the association of APOE and cognitive
trajectories over a period of nearly 30 years, also
accounting for childhood cognitive ability. Limitations
include sample attrition due to participant loss to follow-
up, inherent to all studies of aging populations.25 How-
ever, while not random with respect to cognitive function,
this is unlikely to have altered the pattern of associations
observed. Previous papers have suggested modest asso-
ciations between vascular risk factors, APOE, and cogni-
tion;26,27 yet within this sample only cholesterol showed
associations with APOE genotype. As cholesterol was not
measured in NSHD until age 53, it could not be included
in the longitudinal model from age 43 onward. However,
given the relatively low levels of hypercholesterolaemia
that might be expected at age 43, it is unlikely to have
inﬂuenced associations between cognition and APOE-ε4.
The lack of association between APOE genotype and
childhood cognition is supportive of prior ﬁndings by
Deary et al.28 Consistent with prior work on the NSHD at
age 53 7, no evidence of APOE-associated decline was
found in either processing speed or memory at ages 43, 53
and 60–64. The emergence of signiﬁcantly lower memory
between the ages of 60–69 years in APOE-ε4 carriers is
consistent with prior cross-sectional and change-based
studies 29–31, yet with the availability of multiple previous
cognitive measures, NSHD uniquely pinpointed this age
range as sensitive in this respect. This suggests the pos-
sibility of a time window in which individuals at a higher
risk of cognitive decline can potentially be identiﬁed for
future clinical and public health interventions.
Key to this study, the trajectory of episodic memory
over the near three decades of testing was also found to
show faster decline associated with APOE-ε4 homo-
zygotes. These ﬁndings support those of Caselli et al. 13,
who noted an increased rate of memory decline prior to
age 60 in homozygotic carriers of the ε4 allele, albeit over
a shorter time period in a smaller, age-heterogeneous
sample. The absence of any association with letter search
is similarly consistent with Caselli et al. in parallel work
on the same cohort 32,33,].
The presence of detectable deﬁcits in episodic memory
at age 69 only for APOE-ε4 carriers coupled with a faster
rate of decline leading up to this stage highlights asso-
ciations that had not been noticeable at earlier data col-
lections of NSHD 7. At the cellular level this may be due
to disrupted lipid metabolism resulting in reduced ability
to perform neural re-innervation 2, and a reduced ability
to clear neurotoxic beta amyloid 3. Recent advances in
tau-imaging also suggest the possibility that APOE-ε4 is
associated with enhanced tau deposition in the
medial–temporal regions of the brain, vital for episodic
memory 34. While conﬂicting evidence on ﬁndings related
to APOE genotype and tau pathology exists 35, the latter
may well play a role in the cognitive decline seen in our
study. However, in relation to both potential pathological
mechanisms, it is unclear whether these are gradual
cumulative processes or temporally speciﬁc activations. If
the former, we might expect to see these negative asso-
ciations strengthen with age rather than simply persist.
Episodic memory has been noted in cognitive test bat-
teries to be a highly sensitive marker of incident AD prior
Fig. 1 Cognitive trajectory of total word-learning test score between ages 43 and 69
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to other clinical manifestations 36,37. Rates of diagnosed
Mild Cognitive Impairment and AD are low in NSHD, in
keeping with the comparatively young age of the cohort
when considering these diagnoses. It remains possible
that the detected associations between APOE-ε4 and
episodic memory seen here are attributable to prodromal
AD. Given that this decline over almost three decades
precedes estimations of the functional manifestations of
prodromal AD 38,39, continued follow-up of NSHD will
determine the age-speciﬁc incidence of clinical dementia
in those with the APOE-ε4 allele, in comparison to those
without. Regardless, the possibility of APOE-ε4 being
associated with a process of cognitive decline that begins
subtly in midlife may warrant the search for potential
therapeutic window to these deleterious effects, or the
instigation of a screening process for potential AD, earlier
in the life course.
Data and code availability
Data and code are available on request to the NSHD
Data Sharing Committee. NSHD data sharing policies and
processes meet the requirements and expectations of the
UK Medical Research Council (MRC) policy on sharing of
data from population and patient cohorts. Data requests
should be submitted to mrclha.swiftinfo@ucl.ac.uk; fur-
ther details can be found at http://www.nshd.mrc.ac.uk/
data.aspx. These policies and processes are in place to
ensure that the use of data from this national birth cohort
study is within the bounds of consent given previously by
study members, complies with MRC guidance on ethics
and research governance, and meets rigorous MRC data
security standards.
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